Targeting protein neddylation: A novel therapeutic strategy for the treatment of cancer

Meng Wang, Bruno C. Medeiros, Harry P. Erba, Daniel J. Deangelo, Francis J. Giles, Ronan T Swords

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Introduction: The NEDD8 (neural precursor cell-expressed developmentally downregulated 8) conjugation pathway regulates the post-translational modification of oncogenic proteins. This pathway has important potential for cancer therapeutics. Several proteins vital in cancer biology are regulated by protein neddylation. These observations led to the development of a small molecule inhibitor that disrupts protein neddylation and leads to cancer cell death and important activity in early phase clinical trials. Areas covered: This review provides an extensive coverage of cellular protein homeostasis with particular emphasis on the NEDD8 conjugation pathway. Insights into a new investigational drug that specifically disrupts the NEDD8 pathway are discussed. The clinical data for this agent are also updated. Expert opinion: Neddylation controls key cellular pathways found to be dysregulated in many cancers. Protein neddylation is a relatively under-explored pathway for pharmacologic inhibition in cancer. Selective disruption of this pathway has demonstrated clinical activity in patients with myeloid neoplasms and is worth exploring further in combination with other anti-leukemia agents.

Original languageEnglish
Pages (from-to)253-264
Number of pages12
JournalExpert Opinion on Therapeutic Targets
Volume15
Issue number3
DOIs
StatePublished - Mar 1 2011
Externally publishedYes

Fingerprint

Protein Transport
Neoplasms
Proteins
Down-Regulation
Therapeutics
Investigational Drugs
Expert Testimony
Cell death
Post Translational Protein Processing
Leukemia
Homeostasis
Cell Death
Clinical Trials
Molecules

Keywords

  • Acute myeloid leukemia
  • MLN4924
  • Neddylation
  • Therapy

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Wang, M., Medeiros, B. C., Erba, H. P., Deangelo, D. J., Giles, F. J., & Swords, R. T. (2011). Targeting protein neddylation: A novel therapeutic strategy for the treatment of cancer. Expert Opinion on Therapeutic Targets, 15(3), 253-264. https://doi.org/10.1517/14728222.2011.550877

Targeting protein neddylation : A novel therapeutic strategy for the treatment of cancer. / Wang, Meng; Medeiros, Bruno C.; Erba, Harry P.; Deangelo, Daniel J.; Giles, Francis J.; Swords, Ronan T.

In: Expert Opinion on Therapeutic Targets, Vol. 15, No. 3, 01.03.2011, p. 253-264.

Research output: Contribution to journalArticle

Wang, Meng ; Medeiros, Bruno C. ; Erba, Harry P. ; Deangelo, Daniel J. ; Giles, Francis J. ; Swords, Ronan T. / Targeting protein neddylation : A novel therapeutic strategy for the treatment of cancer. In: Expert Opinion on Therapeutic Targets. 2011 ; Vol. 15, No. 3. pp. 253-264.
@article{5d806963fb6e4486b2a041d543fd4602,
title = "Targeting protein neddylation: A novel therapeutic strategy for the treatment of cancer",
abstract = "Introduction: The NEDD8 (neural precursor cell-expressed developmentally downregulated 8) conjugation pathway regulates the post-translational modification of oncogenic proteins. This pathway has important potential for cancer therapeutics. Several proteins vital in cancer biology are regulated by protein neddylation. These observations led to the development of a small molecule inhibitor that disrupts protein neddylation and leads to cancer cell death and important activity in early phase clinical trials. Areas covered: This review provides an extensive coverage of cellular protein homeostasis with particular emphasis on the NEDD8 conjugation pathway. Insights into a new investigational drug that specifically disrupts the NEDD8 pathway are discussed. The clinical data for this agent are also updated. Expert opinion: Neddylation controls key cellular pathways found to be dysregulated in many cancers. Protein neddylation is a relatively under-explored pathway for pharmacologic inhibition in cancer. Selective disruption of this pathway has demonstrated clinical activity in patients with myeloid neoplasms and is worth exploring further in combination with other anti-leukemia agents.",
keywords = "Acute myeloid leukemia, MLN4924, Neddylation, Therapy",
author = "Meng Wang and Medeiros, {Bruno C.} and Erba, {Harry P.} and Deangelo, {Daniel J.} and Giles, {Francis J.} and Swords, {Ronan T}",
year = "2011",
month = "3",
day = "1",
doi = "10.1517/14728222.2011.550877",
language = "English",
volume = "15",
pages = "253--264",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Targeting protein neddylation

T2 - A novel therapeutic strategy for the treatment of cancer

AU - Wang, Meng

AU - Medeiros, Bruno C.

AU - Erba, Harry P.

AU - Deangelo, Daniel J.

AU - Giles, Francis J.

AU - Swords, Ronan T

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Introduction: The NEDD8 (neural precursor cell-expressed developmentally downregulated 8) conjugation pathway regulates the post-translational modification of oncogenic proteins. This pathway has important potential for cancer therapeutics. Several proteins vital in cancer biology are regulated by protein neddylation. These observations led to the development of a small molecule inhibitor that disrupts protein neddylation and leads to cancer cell death and important activity in early phase clinical trials. Areas covered: This review provides an extensive coverage of cellular protein homeostasis with particular emphasis on the NEDD8 conjugation pathway. Insights into a new investigational drug that specifically disrupts the NEDD8 pathway are discussed. The clinical data for this agent are also updated. Expert opinion: Neddylation controls key cellular pathways found to be dysregulated in many cancers. Protein neddylation is a relatively under-explored pathway for pharmacologic inhibition in cancer. Selective disruption of this pathway has demonstrated clinical activity in patients with myeloid neoplasms and is worth exploring further in combination with other anti-leukemia agents.

AB - Introduction: The NEDD8 (neural precursor cell-expressed developmentally downregulated 8) conjugation pathway regulates the post-translational modification of oncogenic proteins. This pathway has important potential for cancer therapeutics. Several proteins vital in cancer biology are regulated by protein neddylation. These observations led to the development of a small molecule inhibitor that disrupts protein neddylation and leads to cancer cell death and important activity in early phase clinical trials. Areas covered: This review provides an extensive coverage of cellular protein homeostasis with particular emphasis on the NEDD8 conjugation pathway. Insights into a new investigational drug that specifically disrupts the NEDD8 pathway are discussed. The clinical data for this agent are also updated. Expert opinion: Neddylation controls key cellular pathways found to be dysregulated in many cancers. Protein neddylation is a relatively under-explored pathway for pharmacologic inhibition in cancer. Selective disruption of this pathway has demonstrated clinical activity in patients with myeloid neoplasms and is worth exploring further in combination with other anti-leukemia agents.

KW - Acute myeloid leukemia

KW - MLN4924

KW - Neddylation

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=79951663751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951663751&partnerID=8YFLogxK

U2 - 10.1517/14728222.2011.550877

DO - 10.1517/14728222.2011.550877

M3 - Article

C2 - 21219242

AN - SCOPUS:79951663751

VL - 15

SP - 253

EP - 264

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 3

ER -